Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1 个研究点分布在 1 个国家目标入组 27 人开始时间: 2020年5月28日最近更新: 2026年7月27日

适应症

干预措施

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
入组人数: 27
试验地点: 1
主要终点: Fold change in interferon-producing mutant-KRAS-specific cytotoxic (CD8) and helper (CD4) T cells at 16 weeks

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as patients with metastatic colorectal cancer who have exposure to 2 or more lines of chemotherapy, to evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine) with poly-ICLC adjuvant in combination with nivolumab and ipilimumab.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•PDAC or metastatic MSS CRC Cohort:
•Have histologically or cytologically - proven cancer of the pancreas (PDA) or MSS colorectal (CRC) in one of the following categories:
•PDAC must have no evidence of disease and last dose of neoadjuvant and/or adjuvant chemotherapy/radiation therapy/or surgery must be < 6 months from study entry.
•Metastatic MSS CRC after exposure to 2 more lines of chemotherapy in the metastatic setting including 5-flurouracil, irinotecan, and oxaliplatin exposure. Patients treated with FOLFOXIRI may enroll after progression or intolerance to that regimen.
•For metastatic MSS CRC cohort, must have tumor lesions amenable to repeated biopsy, and patient's acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the Principal Investigator).
•For metastatic MSS CRC patients, must have measurable disease per RECIST 1.
•Reinduction Treatment Cohort:
•Have a single site of locoregional recurrence or distant metastasis noted on imaging > 12 months after the first dose of the mutant KRAS peptide vaccine with poly-ICLC adjuvant.
•Have completed definitive treatment for solitary recurrence per standard-of-care (e.g. surgical resection, radiation, and/or chemotherapy) <6 months prior to screening for reinduction treatment.
•Both Cohorts:
•*Age ≥18 years.
•Have sufficient archival tumor tissue for next-generation sequencing (NGS) and immune-phenotyping.
•Have one of the KRAS mutations included in the vaccine at the time of vaccination expressed in tumor.
•Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
•Life expectancy of greater than 6 months.
•Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug.
•Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.
•Men must use acceptable form of birth control while on study.
•Ability to understand and willingness to sign a written informed consent document.

排除标准

•If expected to require any other form of systemic or localized antineoplastic therapy while on study.
•Within 2 weeks prior to first dose of study drug.
•Systemic or topical steroids corticosteroids at immunosuppressive doses (> 10 mg/day of prednisone or equivalent). Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
•Any palliative or adjuvant radiation or gamma knife radiosurgery.
•Any chemotherapy.
•Within 4 weeks prior to first dose of study drug.
•Any investigational cytotoxic drug.
•Any investigational device.
•Has received a live vaccine.
•Received any allergen hyposensitization therapy.
•Received any growth factors, e.g. granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin.
•Any major surgery.
•PDAC or metastatic MSS CRC Cohort: Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4), etc.).
•Hypersensitivity reaction to any monoclonal antibody.
•Known history or evidence of brain metastases.
•Has active autoimmune disease that has required systemic treatment in the past 2 years, or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.
•Known history or concurrent interstitial lung disease.
•Has a pulse oximetry < 92% on room air.
•Requires the use of home oxygen.
•Infection with HIV or hepatitis B or C.
•Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
•Has been diagnosed with another cancer or myeloproliferative disorder within the past 5 year.
•Has a diagnosis of immunodeficiency.
•Presence of any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft. Patients with a history of allogeneic hematopoietic stem cell transplant will be excluded.
•Any other sound medical, psychiatric, and/or social reason as determined by the Investigator.
•Unwilling or unable to follow the study schedule for any reason.
•Are pregnant or breastfeeding.
•For metastatic MSS CRC and Reinduction Treatment Cohorts, any peritoneal involvement by the tumor.
•For metastatic MSS CRC and Reinduction Treatment Cohorts, any radiological or clinical pleural effusions or ascites.
•For metastatic MSS CRC and Reinduction Treatment Cohorts, patients on parenteral nutrition.
•For metastatic MSS CRC and Reinduction Treatment Cohorts, patients with any single liver metastases greater than 5 cm or greater > 50% liver involvement.
•For metastatic MSS CRC and Reinduction Treatment Cohorts, history of malignant bowel obstruction.